Product
Mepolizumab
Aliases
Mepolizumab 100 mg, Mepolizumab 100 MG, Mepolizumab 100 MG [Nucala], Nucala
Name
Mepolizumab
INN Name
mepolizumab
FDA Approved
Yes
41 clinical trials
1 organization
28 indications
15 posters
1 document
Indication
Nasal PolypsIndication
AsthmaIndication
Churg-Strauss SyndromeIndication
Pulmonary DiseaseIndication
Chronic ObstructiveIndication
Hypereosinophilic SyndromeIndication
Chronic RhinosinusitisIndication
Eosinophilic asthmaIndication
SinusitisIndication
Late-Onset AsthmaIndication
Asthma in ChildrenIndication
Chronic Obstructive Pulmonary DiseaseIndication
EosinophiliaIndication
Healthy SubjectsIndication
pharmacokineticsIndication
pharmacodynamicsIndication
EoEIndication
Eosinophilic EsophagitisIndication
Chronic CoughIndication
Eosinophilic BronchitisIndication
Chronic rhinosinusitisIndication
PolypIndication
NasalIndication
Fasciitis, EosinophilicIndication
Aspirin-inducedIndication
Eosinophilic Granulomatous VasculitisClinical trial
A Randomised, Double-blind, Placebo Controlled, Parallel Group Phase III Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) / Eosinophilic Chronic Rhinosinusitis (ECRS) MERIT: Mepolizumab in Eosinophilic Chronic RhinosinusITis StudyStatus: Completed, Estimated PCD: 2023-04-12
Clinical trial
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or BenralizumabStatus: Recruiting, Estimated PCD: 2025-09-26
Clinical trial
A Randomized, Double-blinded, Single-dose, 3-arm Parallel Comparative Study on Pharmacokinetics and Safety of BAT2606 Injection Versus Mepolizumab Injection (EU-licensed Nucala® and US-licensed Nucala®) in Healthy Chinese Male SubjectsStatus: Completed, Estimated PCD: 2023-05-26
Clinical trial
A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) TherapyStatus: Recruiting, Estimated PCD: 2025-10-10
Clinical trial
Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy)Status: Completed, Estimated PCD: 2023-02-16
Clinical trial
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)Status: Active (not recruiting), Estimated PCD: 2024-08-19
Clinical trial
A Phase 4, Open-label, Single Arm, 24-week, Study to Evaluate the Safety and Efficacy of Mepolizumab 100 mg SC Administered Every 4 Weeks in Indian Participants Aged ≥18 Years With Severe Eosinophilic asthMa (PRISM)Status: Recruiting, Estimated PCD: 2023-11-24
Clinical trial
A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic InflammationStatus: Completed, Estimated PCD: 2022-09-07
Clinical trial
A Prospective, Real-World, Interventional Study To Evaluate The Effect Of Mepolizumab On Achieving Clinical Remission In Participants With Severe AsthmaStatus: Not yet recruiting, Estimated PCD: 2026-07-27
Clinical trial
An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of an Autoinjector for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 204959)Status: Completed, Estimated PCD: 2017-11-30
Clinical trial
MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 TrialStatus: Completed, Estimated PCD: 2017-05-31
Clinical trial
A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic SyndromeStatus: Recruiting, Estimated PCD: 2024-09-16
Poster
Mepolizumab Therapy Improves Most Bothersome Symptoms in Patients With Hypereosinophilic SyndromeClinical trial
Evaluation of Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis With Nasal Polyps and Comorbid Severe Eosinophilic Asthma: an Integrative Multi-omics Approach to Assess Biomarker Signatures of Responsive Disease EndotypesStatus: Recruiting, Estimated PCD: 2025-09-03
Clinical trial
Biomarkers Evaluation and Effect of Mepolizumab on Lower and Upper Airways Inflammation in Severe Refractory Eosinophilic Asthma and Nasal PolyposisStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Efficacy of Mepolizumab in Patients With Late-onset Severe Eosinophilic Asthma and Fixed ObstructionStatus: Active (not recruiting), Estimated PCD: 2023-03-15
Clinical trial
Open Label, Observational Study for Children & Adolescent With Severe Asthma With an Eosinophilic Phenotype Treated With MepolizumabStatus: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
Real Life Study Assessing Long Term Outcomes and Predictive Factors of Response to Biologicals in Patients With Severe CRSwNP and/or Severe Allergic and/or Eosinophilic AsthmaStatus: Recruiting, Estimated PCD: 2030-12-31
Clinical trial
Optimisation of Treatment in Patients With CRSwNP. An RCT of Mepolizumab and Surgical Treatment With FESS and Mepolizumab Versus Only Mepolizumab Over a 6- and 12-month Follow-upStatus: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Evaluation of MEpolizumab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind StudyStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Investigating the Effects of Th2 Modulation on the Generation and Persistence of Tissue Adaptive Immune Memory in Chronic Rhinosinusitis With Nasal PolyposisStatus: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Randomised Controlled Trial of Mepolizumab Initiated Following Admission to Hospital for a Severe Exacerbation of Eosinophilic COPDStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 1: Interleukin-5 Antagonists - Mepolizumab and ReslizumabStatus: Completed, Estimated PCD: 2021-04-04
Clinical trial
The Role of IL5 in Epithelial Cell IntegrityStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
How Much Severe is the Severe Asthma of Patients Who Will be Medicated With Mepolizumab? Μeasurement of Respiratory Mechanics by Means of Impulse Oscillometry in Severe Eosinophilic Asthmatics Before and After Mepolizumab InitiationStatus: Completed, Estimated PCD: 2023-10-23
Clinical trial
Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). Can Shedding of Epithelial Barrier Proteins be Used as Biomarker in Severe Asthma With/Out CRSwNP Management?Status: Recruiting, Estimated PCD: 2025-05-15
Clinical trial
Nation-wide Health Resource Consumption and Costs Associated With Mepolizumab (Nucala): a French SNDS Database StudyStatus: Completed, Estimated PCD: 2023-07-31
Clinical trial
Effectiveness of Mepolizumab in the Treatment of Patients With Severe Uncontrolled CRSwNP: a Multicentric Real Life Observational StudyStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
Effect of Mepolizumab on the Phenotype/Proteome/Transcriptome of Eosinophils in Severe Eosinophilic AsthmaStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled DevicesStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Identifying Predictors Of Long-Lasting Response To Mepolizumab In CRSwNP: Is The Disease-Modifying Role Secondary To Restored Anti-Viral Activity Or Enhanced Epithelial Regeneration?Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Novel Insight in pathologiCal and clinicAl Attributes in Response to mepoLizumab Treatment in Patients With Chronic rhInosinusitis With Nasal pOlyPs With or Without bronchIal Asthma on a Long-term Basis (CALIOPI STUDY)Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant SymptomsStatus: Completed, Estimated PCD: 2022-06-06
Clinical trial
A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPDStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Immunological Basis for Mepolizumab Activity in COPDStatus: Not yet recruiting, Estimated PCD: 2024-04-01
Clinical trial
Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study.Status: Not yet recruiting, Estimated PCD: 2024-09-01
Clinical trial
FUNLUM: Functional Lung MRI for Early Treatment Response Assessment and Outcome Prediction for Patients With Severe Eosinophilic Asthma on Anti IL 5 Antibody TherapyStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways DiseasesStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Mepolizumab for the Treatment of Eosinophilic Fasciitis; An Open-Label, Single-Arm, Exploration StudyStatus: Withdrawn, Estimated PCD: 2025-12-01
Clinical trial
Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomised, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy (MANDARA Study)Status: Active (not recruiting), Estimated PCD: 2023-08-10
Clinical trial
Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab TreatmentStatus: Recruiting, Estimated PCD: 2024-12-30
Document
DailyMed Label: NucalaOrganization
GlaxoSmithKline LLC